(Q34579252)

3 August 2017

1 reference

title

Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines (English)

1 reference

3 August 2017

1 reference

J Dutcher

1

1 reference

3 August 2017

M B Atkins

2

1 reference

3 August 2017

K Margolin

3

1 reference

3 August 2017

G Weiss

4

1 reference

3 August 2017

J Clark

5

1 reference

3 August 2017

J Sosman

6

1 reference

3 August 2017

T Logan

7

1 reference

3 August 2017

F Aronson

8

1 reference

3 August 2017

J Mier

9

1 reference

3 August 2017

Cytokine Working Group

10

1 reference

3 August 2017

publication date

1 January 2001

1 reference

3 August 2017

number of pages

11

1 reference

inferred from page(s)

published in

Medical Oncology

1 reference

3 August 2017

volume

18

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

209-219

1 reference

Kaposi's sarcoma. New treatment modalities

3 August 2017

cites work

1 reference

12 December 2020

Interleukin 4 alone and with gamma-interferon or alpha-tumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinomas

1 reference

12 December 2020

Antitumor activity of recombinant interleukin 6 in mice

1 reference

12 December 2020

Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production

1 reference

12 December 2020

Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy

1 reference

12 December 2020

Alterations in platelet function in patients receiving interleukin-6 as cytokine therapy

1 reference

12 December 2020

Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells

1 reference

12 December 2020

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines

1 reference

12 December 2020

Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity

1 reference

12 December 2020

Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory.

1 reference

12 December 2020

Nomenclature of lymphokines which regulate B-lymphocytes.

1 reference

12 December 2020

Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion

1 reference

12 December 2020

Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes

1 reference

12 December 2020

A distinct coagulopathy associated with interleukin-2 therapy

1 reference

12 December 2020

Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma

1 reference

12 December 2020

Interleukin 12: a key modulator of immune function

1 reference

12 December 2020

Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells

1 reference

12 December 2020

A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma

1 reference

12 December 2020

The biology of interleukin-6

1 reference

12 December 2020

Effects of interleukin-2 administration on platelet function in cancer patients

1 reference

12 December 2020

Chest roentgenographic abnormalities in IL-2 recipients. Incidence and correlation with clinical parameters.

1 reference

12 December 2020

Antitumor and antimetastatic activity of interleukin 12 against murine tumors

1 reference

12 December 2020

Interleukin-6 and its receptor: a paradigm for cytokines

1 reference

12 December 2020

Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses.

1 reference

12 December 2020

Role of Interferon-γ in Mediating the Antitumor Efficacy of Interleukin-12

1 reference

12 December 2020

Interleukin-6: an overview

1 reference

12 December 2020

A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo

1 reference

12 December 2020

Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment

1 reference

12 December 2020

Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response

1 reference

12 December 2020

1 reference

12 December 2020

Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice

1 reference

12 December 2020

Morphologic and ultrastructural evidence of interleukin-6 induced platelet activation

1 reference

12 December 2020

The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells

1 reference

12 December 2020

Cardiorespiratory effects of immunotherapy with interleukin-2.

1 reference

12 December 2020

An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy

1 reference

12 December 2020

Identification of a T cell-derived b cell growth factor distinct from interleukin 2.

1 reference

12 December 2020

Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies

1 reference

12 December 2020

Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production

1 reference

12 December 2020

Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma

1 reference

12 December 2020

Identifiers

DOI

10.1385/MO:18:3:209

1 reference

Dimensions Publication ID

3 August 2017

1052059090

0 references

1 reference